Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Jayesh Desai, Guzmán Alonso, Se Hyun Kim, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 271-278
Open Access | Times Cited: 53

Showing 26-50 of 53 citing articles:

Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of Cancer
C. Salva de Torres, Iosune Baraibar, Nadia Saoudi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6967-6967
Open Access | Times Cited: 4
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Tuan Hoang, Erica S. Tsang
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
Identification of Candidate Alterations Mediating KRASG12C Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
Khalid Jazieh, Jill Tsai, Sheila Solomon, et al.
Clinical Cancer Research (2025) Vol. 31, Iss. 5, pp. 899-906
Closed Access
Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer
Emily Harrold, Fergus Keane, Henry Walch, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 12, pp. 2672-2683
Open Access | Times Cited: 2
Assessment of KRASG12C inhibitors for colorectal cancer
Gary A. Piazza, Preethi Chandrasekaran, Yulia Maxuitenko, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
Paolo Ciracì, Vittorio Studiale, Ada Taravella, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 2
KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer
Annie Xiao, Marwan Fakih
Clinical Colorectal Cancer (2024) Vol. 23, Iss. 3, pp. 199-206
Closed Access | Times Cited: 1
Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer
Hirotaka Miyashita, David S. Hong
Journal of Cancer Immunology (2024) Vol. 6, Iss. 2, pp. 62-69
Open Access | Times Cited: 1
Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation
Satoko Ugai, Qian Yao, Yasutoshi Takashima, et al.
Cancer Science (2024) Vol. 115, Iss. 10, pp. 3455-3465
Open Access | Times Cited: 1
Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary
Harry E Fuentes, Pashtoon Murtaza Kasi, Li Ma, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 1
Immunotherapy in Colorectal Cancer: Statuses and Strategies
Yuan Li, Zewei Cheng, Shengli Li, et al.
Heliyon (2024) Vol. 11, Iss. 1, pp. e41354-e41354
Open Access | Times Cited: 1
Targeting mutated KRAS in the first‐line therapy
Hideaki Ijichi
Clinical and Translational Discovery (2024) Vol. 4, Iss. 2
Open Access
State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies
Pieterjan Vanclooster, Sofie Seghers, Hans Prenen
Current Opinion in Oncology (2024) Vol. 36, Iss. 4, pp. 313-319
Closed Access
Redox, cysteines, and kinases—A triad sustaining myeloid leukemia
Vanessa Marensi
Advances in cancer research (2024), pp. 1-68
Closed Access
Association of KRAS Mutation and Gene Pathways in Colorectal Carcinoma: A Transcriptome- and Methylome-Wide Study and Potential Implications for Therapy
Farzana Jasmine, Armando Almazan, Yuliia Khamkevych, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8094-8094
Open Access
Chemotherapie, gezielte Therapie und Immuntherapie des metastasierten kolorektalen Karzinoms
Mirjam Richard, Christine Koch, Jörg Trojan
Deleted Journal (2024) Vol. 19, Iss. 5, pp. 432-438
Closed Access
Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS-mutated colorectal cancer
Susmita Ghosh, Fan Fan, Reid T. Powell, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Study of the mass balance, biotransformation, and safety of [<sup>14</sup>C]IBI351 in healthy Chinese subjects
Shuaishuai Wang, Wen Han Lin, Bilal Ahmed, et al.
Journal of Biomedical Research (2024) Vol. 38, pp. 1-1
Open Access
Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors
Eylül Özgü, Benjamin G. Kaplan, Smruthy Sivakumar, et al.
BJC Reports (2024) Vol. 2, Iss. 1
Open Access
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration
Roberto Moretto, Daniele Rossini, Sabina Murgioni, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access
KRAS inhibitors in drug resistance and potential for combination therapy
Lala S. Rathod, Nikhil S. Sakle, Santosh N. Mokale
Tumori Journal (2024)
Closed Access
LRP1B associated with immune cell infiltration influenced the efficacy of immunotherapy in colorectal cancer patients
Weiming Weng, Shengquan He, Guoxiong Zhang, et al.
Clinics (2024) Vol. 79, pp. 100516-100516
Open Access
Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer types
Zahra Davoudi, Thomas S. Dexheimer, Nathan P. Coussens, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS-mutated colorectal cancer
Susmita Ghosh, Fan Fan, Reid T. Powell, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access

Scroll to top